Cargando…
PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials
Systemic sclerosis- (SSc-) related vasculopathy, as manifested by Raynaud's Phenomenon (RP) and digital ulcers (DUs), is associated with significant impairment of the quality of life and morbidity. The current vasoactive approach for SSc-RP, although employing vasodilators, is entirely off-labe...
Autores principales: | Impens, Ann J., Phillips, Kristine, Schiopu, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216380/ https://www.ncbi.nlm.nih.gov/pubmed/22121375 http://dx.doi.org/10.1155/2011/392542 |
Ejemplares similares
-
Digital Ischemia in Scleroderma Spectrum of Diseases
por: Schiopu, Elena, et al.
Publicado: (2010) -
Lower limb ulcer and Raynaud's phenomenon
por: Chérif, Mohammad Yassine, et al.
Publicado: (2022) -
Absence of Scleroderma pattern at nail fold capillaroscopy valuable in the exclusion of Scleroderma in unselected patients with Raynaud’s Phenomenon
por: Bissell, Lesley-Anne, et al.
Publicado: (2016) -
Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis
por: Arefiev, Kait, et al.
Publicado: (2011) -
Rheopheresis for Digital Ulcers and Raynaud's Phenomenon in Systemic Sclerosis Refractory to Conventional Treatments
por: Korsten, Peter, et al.
Publicado: (2019)